drugset
Drugs / rAAV.hCNGA3
last change Jun 2020 re-read 3 minutes ago

rAAV.hCNGA3

also known as AAV8.CNGA3

Gene therapy (AAV / viral vector) targets CNGA3

Developed for
CNGA3-related retinopathy
Investigated by
Ludwig-Maximilians - University of Munich · STZ eyetrial · University Hospital Tuebingen

Trials 1

today NCT02610582 · Ph 1/2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02610582 Nov 2015 → Jun 2027 expected CNGA3-related retinopathy STZ eyetrial Active not recruiting Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as rAAV.hCNGA3 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02610582 ↗
Known as AAV8.CNGA3 “supplemental gene therapy with adeno-associated virus (AAV) encoding CNGA3 (AAV8.CNGA3) in patients with CNGA3-linked achromatopsia” PMID 32352493 ↗ Jun 2020
Modality Gene therapy (AAV / viral vector) “supplemental gene therapy with adeno-associated virus (AAV) encoding CNGA3 (AAV8.CNGA3)” PMID 32352493 ↗ Jun 2020
Target CNGA3 “adeno-associated virus (AAV) encoding CNGA3 (AAV8.CNGA3)” PMID 32352493 ↗ Jun 2020